Balance Sheet
Cash Flow Statement
Beginning Cash BalanceBeginning Cash BalanceCash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesPreferred Shares IssuedShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mangoceuticals (MGRX) Share-based Compensation (2023 - 2025)

Mangoceuticals' Share-based Compensation history spans 3 years, with the latest figure at $9.5 million for Q4 2025.

  • On a quarterly basis, Share-based Compensation rose 398.54% to $9.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $10.7 million, a 408.8% increase, with the full-year FY2025 number at $10.7 million, up 408.8% from a year prior.
  • Share-based Compensation hit $9.5 million in Q4 2025 for Mangoceuticals, up from $1.1 million in the prior quarter.
  • Over the last five years, Share-based Compensation for MGRX hit a ceiling of $9.5 million in Q4 2025 and a floor of -$1.8 million in Q2 2025.
  • Historically, Share-based Compensation has averaged $1.1 million across 3 years, with a median of $612450.0 in 2024.
  • Biggest five-year swings in Share-based Compensation: soared 1157.8% in 2024 and later tumbled 327.18% in 2025.
  • Tracing MGRX's Share-based Compensation over 3 years: stood at -$547287.0 in 2023, then soared by 448.73% to $1.9 million in 2024, then surged by 398.54% to $9.5 million in 2025.
  • Business Quant data shows Share-based Compensation for MGRX at $9.5 million in Q4 2025, $1.1 million in Q3 2025, and -$1.8 million in Q2 2025.